Patents by Inventor Magnus Axelson
Magnus Axelson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8389747Abstract: The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9? have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, artherosclerosis and acromegaly. A preferred compound is picropodophyllin.Type: GrantFiled: July 23, 2009Date of Patent: March 5, 2013Assignee: Axelar ABInventors: Olle Larsson, Magnus Axelson
-
Publication number: 20110178050Abstract: There is disclosed use of certain picro derivatives of cyclolignans for prophylaxis or treatment of diseases or conditions characterised by a hyperactive immune system. Examples of cyclolignans according to the invention include picropodophyllin, deoxypicropodophyllin, anhydropicropodophyllol or deoxyanhydropicropodophyllol.Type: ApplicationFiled: June 18, 2009Publication date: July 21, 2011Applicant: Axelar ABInventors: Magnus Axelson, Olle Larsson
-
Publication number: 20100227797Abstract: There is disclosed use of certain cyclolignans for prophylaxis or treatment of diabetes mellitus type 2, nephropathy, retinopathy, macular degeneration, retinopathy of prematurity, central retinal vein occlusion, branch retinal vein occlusion, rubeotic glaucoma, thyroid eye disease, corneal graft rejection and corneal chemical burns; and for contraception. Preferred compounds are picropodophyllin, deoxypicropodophyllin and anhydropicropodophyllol. There is also described a method of treatment of an eye disease.Type: ApplicationFiled: February 23, 2007Publication date: September 9, 2010Applicant: AXELAR ABInventors: Magnus Axelson, Olof Danielsson, Mario-Alexander Economou, Olle Larsson
-
Publication number: 20100216728Abstract: The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9? have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, artherosclerosis and acromegaly. A preferred compound is picropodophyllin.Type: ApplicationFiled: February 26, 2010Publication date: August 26, 2010Applicant: AXELAR ABInventors: Olle LARSSON, Magnus Axelson
-
Patent number: 7709526Abstract: Compounds which inhibit the insulin-like growth factor-1 receptor (IGF-1 R) and methods for using them for treating IGF-1 R dependent diseases, such as cancer.Type: GrantFiled: February 3, 2006Date of Patent: May 4, 2010Assignee: Biovitrum ABInventors: Olle Larsson, Magnus Axelson
-
Patent number: 7662851Abstract: The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9? have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, atherosclerosis and acromegaly. A preferred compound is picropodophyllin.Type: GrantFiled: January 29, 2008Date of Patent: February 16, 2010Assignee: Axelar ABInventors: Olle Larsson, Magnus Axelson
-
Publication number: 20090326248Abstract: The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9? have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, artherosclerosis and acromegaly. A preferred compound is picropodophyllin.Type: ApplicationFiled: July 23, 2009Publication date: December 31, 2009Applicant: AXELAR ABInventors: Olle LARSSON, Magnus Axelson
-
Patent number: 7629381Abstract: The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9? have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, artherosclerosis and acromegaly. A preferred compound is picropodophyllin.Type: GrantFiled: January 29, 2008Date of Patent: December 8, 2009Assignee: Axelar ABInventors: Olle Larsson, Magnus Axelson
-
Publication number: 20080221207Abstract: The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9? have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, atherosclerosis and acromegaly. A preferred compound is picropodophyllin.Type: ApplicationFiled: January 29, 2008Publication date: September 11, 2008Applicant: AXELAR ABInventors: Olle LARSSON, Magnus Axelson
-
Publication number: 20080119528Abstract: The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9? have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, artherosclerosis and acromegaly. A preferred compound is picropodophyllin.Type: ApplicationFiled: January 29, 2008Publication date: May 22, 2008Applicant: AXELAR ABInventors: Olle LARSSON, Magnus Axelson
-
Patent number: 7348358Abstract: The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9? have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, artherosclerosis and acromegaly. A preferred compound is picropodophyllin.Type: GrantFiled: June 19, 2002Date of Patent: March 25, 2008Assignee: Axelar ABInventors: Olle Larsson, Magnus Axelson
-
Publication number: 20070123491Abstract: The invention refers to new compounds, e.g. podophyllotoxin derivatives, as well as to the use thereof and of known compounds as specific inhibitors of the insulin-like growth factor-1 receptor (IGF-1R). Said compounds can be used for treatment of IGF-1/IGF-1R dependent diseases, such as cancer, psoriasis, arteriosclerosis, certain endocrine and metabolic disorders etc.Type: ApplicationFiled: April 15, 2004Publication date: May 31, 2007Applicant: BIOVITRUM ABInventors: Magnus Axelson, Olle Larsson
-
Publication number: 20060154982Abstract: Compounds which inhibit the insulin-like growth factor-1 receptor (IGF-1 R) and methods for using them for treating IGF- 1 R dependent diseases, such as cancer.Type: ApplicationFiled: February 3, 2006Publication date: July 13, 2006Applicant: AXELAR ABInventors: Olle Larsson, Magnus Axelson
-
Publication number: 20040186169Abstract: The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9′ have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-IR dependent diseases, such as cancer, psoriasis, artherosclerosis and acromegaly. A preferred compound is picropodophyllin.Type: ApplicationFiled: December 19, 2003Publication date: September 23, 2004Inventors: Olle Larsson, Magnus Axelson
-
Publication number: 20040167208Abstract: The invention refers to new compounds and the use thereof as well as the use of known cyclolignans having a trans configuration of the lactone ring as inhibitors of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, especially cancer. Especially deoxypodophyllotoxin can be used for treatment of leukemia in humans.Type: ApplicationFiled: December 19, 2003Publication date: August 26, 2004Inventors: Olle Larsson, Magnus Axelson